Volume 4, Issue 10, Pages e465-e474 (October 2017)

Slides:



Advertisements
Similar presentations
The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis  Dr Michael Roerecke, PhD, Prof Janusz Kaczorowski,
Advertisements

Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia:
Volume 4, Issue 10, Pages e465-e474 (October 2017)
Effect of a bereavement support group on female adolescents' psychological health: a randomised controlled trial in South Africa  Prof Tonya Renee Thurman,
Disparities and change over time in distance women would need to travel to have an abortion in the USA: a spatial analysis  Dr Jonathan M Bearak, PhD,
Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study  Dr Brian G Williams, PhD, Somya Gupta, MA,
Total and cause-specific mortality before and after the onset of the Greek economic crisis: an interrupted time-series analysis  Ioannis Laliotis, PhD,
Demographic and practice factors predicting repeated non-attendance in primary care: a national retrospective cohort analysis  David A Ellis, PhD, Ross.
The commercial determinants of health
Natural environments and suicide mortality in the Netherlands: a cross-sectional, ecological study  Marco Helbich, PhD, Derek de Beurs, PhD, Prof Mei-Po.
Assessment of progress towards universal health coverage for people with disabilities in Afghanistan: a multilevel analysis of repeated cross-sectional.
The number of privately treated tuberculosis cases in India: an estimation from drug sales data  Dr Nimalan Arinaminpathy, DPhil, Deepak Batra, PGDM,
Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation 
Effects of community health interventions on under-5 mortality in rural Guinea-Bissau (EPICS): a cluster-randomised controlled trial  Dr Peter Boone,
Prevalence of cerebral palsy in Uganda: a population-based study
Do air quality alerts benefit public health? New evidence from Canada
Gender myths in global health
Volume 2, Issue 4, Pages e159-e168 (April 2015)
Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness.
Effective cross-sector collaborations create sustainability
Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an.
Assessment of epidemic projections using recent HIV survey data in South Africa: a validation analysis of ten mathematical models of HIV epidemiology.
Volume 17, Issue 9, Pages (September 2016)
Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study  Dr Brian G Williams, PhD, Somya Gupta, MA,
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia:
Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a Markov model analysis  Dr Ana Requena-Méndez,
Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation 
Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study  Mark Jit, PhD, Marc Brisson, PhD, Allison Portnoy,
Volume 3, Issue 12, Pages e592-e600 (December 2016)
Current and future trends in tuberculosis incidence in New York City: a dynamic modelling analysis  Dr Anthony T Fojo, MD, Natalie L Stennis, MPH, Andrew.
Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study  Michael A Irvine,
Disparities and change over time in distance women would need to travel to have an abortion in the USA: a spatial analysis  Dr Jonathan M Bearak, PhD,
Changes in chlamydia prevalence and duration of infection estimated from testing and diagnosis rates in England: a model-based analysis using surveillance.
Volume 392, Issue 10146, Pages (August 2018)
Sherif M Abdalla, Robert Bortolussi, Noni E MacDonald 
Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis  Cynthia Chen, PhD, Francisco Cervero Liceras, MSc, Stefan.
Associations between fast food and physical activity environments and adiposity in mid- life: cross-sectional, observational evidence from UK Biobank 
Effectiveness of a lifestyle intervention led by female community health volunteers versus usual care in blood pressure reduction (COBIN): an open-label,
Risk of poor development in young children in low-income and middle-income countries: an estimation and analysis at the global, regional, and country.
Volume 392, Issue 10144, Pages (July 2018)
Effect of a bereavement support group on female adolescents' psychological health: a randomised controlled trial in South Africa  Prof Tonya Renee Thurman,
Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis  Dr Shevanthi Nayagam,
Sufang Guo, Nuzhat Rafique, Danzhen You, Douglas J Noble 
Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models  Daniel Keebler,
Forecasting the care needs of the older population in England over the next 20 years: estimates from the Population Ageing and Care Simulation (PACSim)
Volume 393, Issue 10178, Pages (March 2019)
Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study  Krishna P Reddy,
Effective interventions for unintentional injuries: a systematic review and mortality impact assessment among the poorest billion  Andres I Vecino-Ortiz,
Volume 3, Issue 2, Pages e94-e104 (February 2016)
Thank you to our diverse (but not diverse enough) reviewers
Volume 373, Issue 9672, Pages (April 2009)
Matthieu J Guitton  The Lancet Planetary Health 
Estimation of PM2·5-associated disease burden in China in 2020 and 2030 using population and air quality scenarios: a modelling study  Qing Wang, PhD,
Acute myocardial infarction hospital admissions and deaths in England: a national follow-back and follow-forward record-linkage study  Perviz Asaria,
Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness.
Volume 375, Issue 9723, Pages (April 2010)
Spatial lifecourse epidemiology
Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people.
Buyun Liu, Yangbo Sun, Wei Bao  The Lancet Planetary Health 
Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label.
Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation 
Ethnoracial and social trends in breast cancer staging at diagnosis in Brazil, 2001–14: a case only analysis  Prof Isabel dos-Santos-Silva, PhD, Prof.
Health systems' capacity to provide post-abortion care: a multicountry analysis using signal functions  Onikepe O Owolabi, PhD, Ann Biddlecom, PhD, Hannah.
Jeffrey T Howard, Alexis R Santos-Lozada  The Lancet Planetary Health 
Deriving a practical framework for the evaluation of health apps
The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis  Dr Michael Roerecke, PhD, Prof Janusz Kaczorowski,
Economic decline, incarceration, and mortality from drug use disorders in the USA between 1983 and 2014: an observational analysis  Elias Nosrati, PhD,
Institutional challenges to achieving health equity in Ecuador
Sickle cell disease: a new era
Trends in temperature-related age-specific and sex-specific mortality from cardiovascular diseases in Spain: a national time-series analysis  Hicham Achebak,
Presentation transcript:

Volume 4, Issue 10, Pages e465-e474 (October 2017) Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis  Dr Rebecca F Baggaley, PhD, Michael A Irvine, PhD, Werner Leber, PhD, Valentina Cambiano, PhD, Jose Figueroa, MFPH, Heather McMullen, PhD, Prof Jane Anderson, FRCP, Andreia C Santos, PhD, Fern Terris-Prestholt, PhD, Alec Miners, PhD, Prof T Déirdre Hollingsworth, PhD, Prof Chris J Griffiths, DPhil  The Lancet HIV  Volume 4, Issue 10, Pages e465-e474 (October 2017) DOI: 10.1016/S2352-3018(17)30123-6 Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

Figure 1 Schematic illustrating HIV screening model structure Background death rate is applied to each compartment but, for clarity, is not shown. Numbers refer to stages of HIV infection: 1=acute infection; 2=CD4 count of more than 500 cells per μL; 3=CD4 count of 350–500 cells per μL; 4=CD4 count of 200–349 cells per μL; and 5=CD4 count of less than 200 cells per μL. Diagnosis rate for compartment 1 is assumed to be zero (ie, no diagnoses occur during acute infection). Model assumed diagnosis upon progression to AIDs (appendix p 3). The Lancet HIV 2017 4, e465-e474DOI: (10.1016/S2352-3018(17)30123-6) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

Figure 2 Outcomes of the RHIVA2 intervention (A) Cumulative QALYs gained as a result of the RHIVA2 trial over time. The intervention is continued for 28 months only (the duration of the RHIVA2 trial). (B) ICER of cost per QALY gained as a result of the RHIVA2 trial, over time, for the three explored scenarios of increased long-term health-care costs for patients diagnosed with late infection. The grey band represents the £20 000–30 000 threshold of cost-effectiveness of interventions used by NICE in the UK. (C) Scenario lines show additional cost of RHIVA2 against QALYs gained, over time, highlighting each 5 year increment since start of the intervention (shown as coloured dots). Shaded grey area represents the NICE threshold of cost-effectiveness. QALY=quality-adjusted life-year. ICER=incremental cost-effectiveness ratio. NICE=National Institute for Health and Care Excellence. The Lancet HIV 2017 4, e465-e474DOI: (10.1016/S2352-3018(17)30123-6) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

Figure 3 Tornado plot of model parameters varied in univariate sensitivity analysis of scenario 1 Parameters are arranged from widest range of model outcome, with range of model input values shown in parentheses. Dashed line represents ICER estimate for 40 years after RHIVA2 intervention using base case values of all parameters (appendix pp 16–18). Model parameters varied in univariate sensitivity analysis with minimal effect on the ICER (ie, even less than the parameter quality of life multiplier for identified asymptomatic infections, first year) are not shown. ART=antiretroviral therapy. ICER=incremental cost-effectiveness ratio. *Quality of life multiplier. The Lancet HIV 2017 4, e465-e474DOI: (10.1016/S2352-3018(17)30123-6) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

Figure 4 Model sensitivity to assumptions on change in sexual behaviour after diagnosis, quality of life, and QALY and cost discount rates Scenario analyses exploring the sensitivity of model results to different (A) levels of reduction in sexual behaviour among people upon HIV diagnosis; (B) assumptions regarding quality of life after diagnosis; and (C) QALY and cost discount rates. The NICE threshold for cost-effectiveness of £20 000–30 000 is shown in grey. QALY=quality-adjusted life-year. NICE=National Institute for Health and Care Excellence. The Lancet HIV 2017 4, e465-e474DOI: (10.1016/S2352-3018(17)30123-6) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions